Ascendis Pharma A/S (ASND)

NASDAQ: ASND · IEX Real-Time Price · USD
146.04
-5.00 (-3.31%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-3.31%
Market Cap 8.27B
Revenue (ttm) 296.35M
Net Income (ttm) -534.94M
Shares Out 56.61M
EPS (ttm) -9.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 305,361
Open 151.14
Previous Close 151.04
Day's Range 144.36 - 152.53
52-Week Range 66.03 - 161.00
Beta 0.51
Analysts Buy
Price Target 161.56 (+10.63%)
Earnings Date Apr 25, 2024

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 28, 2015
Employees 879
Stock Exchange NASDAQ
Ticker Symbol ASND
Full Company Profile

Financial Performance

In 2023, ASND's revenue was 266.72 million, an increase of 421.20% compared to the previous year's 51.17 million. Losses were -481.45 million, -17.45% less than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $161.56, which is an increase of 10.63% from the latest price.

Price Target
$161.56
(10.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

3 days ago - Market Watch

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Bi...

5 weeks ago - GlobeNewsWire

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a ...

2 months ago - GlobeNewsWire

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Scienc...

2 months ago - GlobeNewsWire

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, Fe...

2 months ago - GlobeNewsWire

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) ...

2 months ago - GlobeNewsWire

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company creat...

2 months ago - GlobeNewsWire

Ascendis Pharma Introduces Vision 2030

COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascen...

3 months ago - GlobeNewsWire

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapies Two of the therapies are already internationally a...

3 months ago - PRNewsWire

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President...

3 months ago - GlobeNewsWire

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from the blinded and ongoing open-label extension (OLE) portions of ACcomplisH, t...

4 months ago - GlobeNewsWire

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

–   On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared t...

4 months ago - GlobeNewsWire

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted ...

4 months ago - GlobeNewsWire

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

–   Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan

4 months ago - GlobeNewsWire

Ascendis Pharma Reports Third Quarter 2023 Financial Results

COPENHAGEN, Denmark, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2023 and provided business updates...

5 months ago - GlobeNewsWire

Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission

• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-November ...

5 months ago - GlobeNewsWire

Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

—  Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination...

6 months ago - GlobeNewsWire

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer ...

6 months ago - GlobeNewsWire

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maint...

6 months ago - GlobeNewsWire

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit

7 months ago - GlobeNewsWire

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

-   Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024

7 months ago - GlobeNewsWire

Ascendis Pharma Reports Second Quarter 2023 Financial Results

COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2023 and provided business updates.

7 months ago - GlobeNewsWire

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m 2 , the threshold for kidney dysfunction, receiving TransCon PTH experienced eGFR improvement to above 60 mL/min/1.73m...

7 months ago - GlobeNewsWire

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes

7 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Three Upcoming Investor Presentations

COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice Presi...

8 months ago - GlobeNewsWire